Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A diffuse large B-cell lymphoma that is categorized as ST2 with high probability by the LymphGen algorithm. This is based on a combination of genetic features and ST2 DLBCLs often, but do not always, have missense or nonsense mutations affecting TET2 and NFKBIA. This subgroup also commonly has mutations due to aberrant somatic hypermutation affecting some combination of SGK1, ZFP36L1, SOCS1, HIST1H1E and CD83, which can be coding or non-coding.
Biomarker and diagnostic research for ST2 diffuse large B-cell lymphoma has been reported in the published literature.
No clinical trials have been registered for ST2 diffuse large B-cell lymphoma.
10 publications have been identified in PubMed for ST2 diffuse large B-cell lymphoma. Research spans Diagnostic / Biomarker (40%), Basic Science / Preclinical (30%), and Epidemiology / Natural History (20%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 4 | 40% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 1:58 AM UTC
Common questions about ST2 diffuse large B-cell lymphoma
Laboratory research
3 |
30% |
Disease patterns and progression | 2 | 20% |
Clinical study results | 1 | 10% |
Yim J (2026). [PMID: 41544233](https://pubmed.ncbi.nlm.nih.gov/41544233/). *Blood Adv*. [Diagnostic / Biomarker]
Ghamlouch H (2026). [PMID: 41536808](https://pubmed.ncbi.nlm.nih.gov/41536808/). *Hemasphere*. [Basic Science / Preclinical]
Wu YF (2025). [PMID: 39492801](https://pubmed.ncbi.nlm.nih.gov/39492801/). *Cancer Sci*. [Diagnostic / Biomarker]
Shen YG (2025). [PMID: 40715072](https://pubmed.ncbi.nlm.nih.gov/40715072/). *Signal Transduct Target Ther*. [Clinical Trial Publication]
Zhao P (2025). [PMID: 39641321](https://pubmed.ncbi.nlm.nih.gov/39641321/). *Hematol Oncol*. [Epidemiology / Natural History]
Zhang XY (2025). [PMID: 40907571](https://pubmed.ncbi.nlm.nih.gov/40907571/). *Cancer Res Treat*. [Diagnostic / Biomarker]
Moia R (2025). [PMID: 39825831](https://pubmed.ncbi.nlm.nih.gov/39825831/). *Blood Adv*. [Epidemiology / Natural History]
Dondolin R (2025). [PMID: 40629066](https://pubmed.ncbi.nlm.nih.gov/40629066/). *Leukemia*. [Diagnostic / Biomarker]
Pomares AA (2025). [PMID: 40067847](https://pubmed.ncbi.nlm.nih.gov/40067847/). *PLoS One*. [Basic Science / Preclinical]
Sciarra R (2024). [PMID: 38442902](https://pubmed.ncbi.nlm.nih.gov/38442902/). *Br J Haematol*. [Basic Science / Preclinical]